Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost: A dose-escalation feasibility study

Savino Cilla, Francesco Deodato, Gianluca Ianiro, Gabriella Macchia, Vincenzo Picardi, Milly Buwenge, Silvia Cammelli, Alice Zamagni, Vincenzo Valentini, Alessio G. Morganti, Alessio Giuseppe Morganti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)


Purpose: This study aimed to assess the feasibility to plan and deliver highly heterogeneous doses to symptomatic large tumors using volumetric modulated arc therapy (VMAT) and simultaneous integrated boost (SIB) during a short course palliative accelerated radiotherapy. Methods: A patient with a large symptomatic chordoma infiltrating the right gluteal region was selected. A modified SIB treatment was implemented to irradiate the central volume of the tumor (boost target volume, BTV) up to 10 Gy/fraction in a dose escalation trial while maintaining the remaining tumor volume (planning target volume, PTV) and the surrounding healthy tissues within 5 Gy/fraction in twice daily fractions for two consecutive days. Four SIB plans were generated in the dual-arc modality; a basal dose of 20 Gy was prescribed to the PTV, while the BTV was boosted up to 40 Gy. For comparison purposes, plans obtained with a sequential boost (SEQ plans) were also generated. All plans were optimized to deliver at least 95% of the prescription dose to the targets. Dose contrast index (DCI), conformity index (CI), integral dose (ID), and the irradiated body volumes at 5, 10, and 20 Gy were evaluated. Results: At equal targets coverage, SIB plans provided major improvement in DCI, CI, and ID with respect to SEQ plans. When BTV dose escalated up to 200% of PTV prescription, DCI resulted in 66% for SIB plans and 37% for SEQ plans; the ID increase was only 11% for SIB plans (vs 27% for SEQ plans) and the increase in healthy tissues receiving more than 5, 10, and 20 Gy was less than 2%. Pretreatment dose verification reported a γ-value passing rate greater than 95% with 3%(global)-2 mm. Conclusion: A modified SIB technique is dosimetrically feasible for large tumors, where doses higher than the tolerance dose of healthy tissues are necessary to increase the therapeutic gain.
Lingua originaleEnglish
pagine (da-a)35-43
Numero di pagine9
RivistaJournal of Applied Clinical Medical Physics
Stato di pubblicazionePubblicato - 2018


  • Aged
  • Chordoma
  • Feasibility Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Prognosis
  • Radiometry
  • Radiotherapy Dosage
  • Radiotherapy Planning, Computer-Assisted
  • Radiotherapy, Intensity-Modulated
  • VMAT
  • palliative
  • simultaneous integrated boost


Entra nei temi di ricerca di 'Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost: A dose-escalation feasibility study'. Insieme formano una fingerprint unica.

Cita questo